- Cardinal Health is one of the beneficiaries of the growing biosimilar market.
- Its medical segment is struggling but its pharmaceutical segment offsets this with a 13% growth rate YoY, resulting in a 12.55 percent YoY increase in its top line.
- Management approved a $3 billion increase to its share repurchase program and intends to purchase up to $1 billion of its own stock this fiscal year.
- Its bottom line increased in comparison to pre-pandemic levels, resulting in an improved earnings per share and return on equity.
- Cardinal Health's trading is relatively cheap in comparison to its peers.
For further details see:
Cardinal Health Pivots Towards Profit Despite $6.37B Settlement